% | $
Quotes you view appear here for quick access.

Spectrum Pharmaceuticals, Inc. Message Board

  • iamthestockmarket iamthestockmarket May 15, 2013 7:26 PM Flag

    Feuerstein twetted this about an hour ago, reason for pop

    Sit down, I'm about to say something nice about $SPPI: Belinostat ph 3 data pretty good.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • cant find news on google -old news -yes-

      Sentiment: Strong Buy

      • 2 Replies to amgnjim
      • Favorable safety profile
        On January 24, 2013, Topotarget announced that preliminary safety data from the BELIEF trial in PTCL, presented at the T-Cell Lymphoma Forum 2013 in San Francisco, USA, showed that belinostat has a favorable safety profile and that the compound has the potential to become a well-tolerated alternative for the treatment of PTCL. The favorable safety outcome from this trial, as well as experience from earlier belinostat trials, shows that full doses of belinostat can be combined with other cytotoxic regimens making combination therapy for cancer patients feasible. The low incidence of myelosuppression is of special notice as this offers the opportunity to combine belinostat with other cytostatic agents for the treatment of patients with PTCL.

        New Drug Application
        Belinostat is currently being developed jointly by Topotarget and Spectrum Pharmaceuticals. Spectrum possesses the commercial rights to market belinostat in North America and India. A New Drug Application (NDA) for belinostat in PTCL is expected to be filed with the FDA by Spectrum in mid-2013.

        Sentiment: Strong Buy

      • Final top-line data confirm that the primary endpoint was met for the belinostat pivotal trial for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with an encouraging objective response rate.

        Top-line data show an objective response rate (ORR) in the efficacy analysis set which is above the protocol criterion for a positive outcome of the trial. Belinostat thus has an ORR that is on par with the accelerated approved drugs Folotyn™ and Istodax®. A Special Protocol Assessment agreement with the US Food and Drug Administration (FDA) required the CLN-19 BELIEF trial to reach an ORR of at least 20%. The FDA has granted belinostat Orphan Drug and Fast Track designation for the treatment of PTCL. All patients who received at least one dose of belinostat and had a confirmed PTCL diagnosis by the central pathology review were included in the efficacy analysis set. The responses have been confirmed by central independent radiology review. Final data have been submitted for presentation to the 2013 ASCO annual meeting.

        “Our belief in belinostat has never wavered and the encouraging objective response rate together with the earlier announced favorable safety profile further supports the potential of our product. We strive to improve the lives of cancer patients and this is a large step in the right direction" said Anders Vadsholt, CEO of Topotarget.

        Sentiment: Strong Buy

5.97-0.120(-1.97%)Apr 17 4:00 PMEDT